NASDAQ · Biotechnology

Phathom Pharmaceuticals, Inc. (PHAT) Stock

$7.17 +0.49% NASDAQ: PHAT Healthcare

Valuation

MetricValue
Price$7.17
Market Cap$579.66M
P/E Ratio-5.32
P/B Ratio-1.66
P/S Ratio2.30
EPS (TTM)$-3.03
52-Week High$18.31
52-Week Low$2.21
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE25.70%
ROA-30.29%
ROCE-23.45%
Gross Margin-91.43%
Operating Margin-91.43%
Net Margin-41.34%
Debt/Equity-0.49
Current Ratio1.73

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$1.0M$55.0M$175.0M
Operating Profit$-135.0M$-172.0M$-167.0M$-277.0M$-160.0M
Net Profit$-144.0M$-198.0M$-202.0M$-334.0M$-221.0M
EPS$-4.00$-5.70$-3.93$-5.29$-3.03
Op Margin——-24532.5%-502.2%-91.4%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$189.0M$165.0M$414.0M$378.0M$259.0M
Total Liabilities$117.0M$240.0M$487.0M$632.0M$697.0M
Cash$183.0M$155.0M$381.0M$297.0M$130.0M
Borrowings$91.0M$97.0M$139.0M$202.0M$212.0M

Latest News

Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026 GlobeNewswire · Jul 20, 2026 Phathom Pharmaceuticals Completes Patient Enrollment for Phase 2 Trial of Voquezna MT Newswires · Jun 23, 2026 Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE) GlobeNewswire · Jun 23, 2026 Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences GlobeNewswire · May 22, 2026 Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting GlobeNewswire · May 20, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-148.0M$-147.0M$-138.0M$-267.0M$-167.0M
Investing Cash Flow$-1.0M$-2.0M$-3.0M$0$0
Financing Cash Flow$2.0M$0$173.0M$2.0M$-2.0M
Net Cash Flow$-104.0M$-28.0M$228.0M$-84.0M$-167.0M
Free Cash Flow$-149.0M$-148.0M$-139.0M$-267.0M$-167.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.03
EV / EBITDA-15.24
FCF Yield-6.66%
Quick Ratio1.87
Interest Coverage-0.64
Return 1Y35.36%
Return 3Y-14.26%
Return 5Y-67.76%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARDXArdelyx, Inc. $3.25 -0.61% -15.13 $802.84M 0.00%

About Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. is led by CEO Steven L. Basta, employs 427 people, headquartered in US, publicly traded since 2019.

Phathom Pharmaceuticals, Inc. (PHAT) stock trades at $7.17 with a market capitalization of $579.66M. The stock is valued at a price-to-earnings (P/E) ratio of -5.32, price-to-book of -1.66, price-to-sales of 2.30. Over the past 52 weeks the stock has ranged between $2.21 and $18.31, and currently trades 60.8% below its 52-week high.

On profitability, Phathom Pharmaceuticals, Inc. generates a return on equity (ROE) of 25.70% — well above the market average, a sign of a high-quality business, return on capital employed of -23.45%, an operating margin of -91.43%, a net profit margin of -41.34%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1176.71 +0.61% JNJ Johnson & Johnson $261.15 +1.82% ABBV AbbVie Inc. $277.39 +1.82% MRK Merck & Company, Inc. Common Stock (new) $146.33 +2.77% UNH UnitedHealth Group Incorporated Common Stock (DE) $378.12 +1.93% NVS Novartis AG $143.26 +0.10% AZN AstraZeneca PLC $159.37 +0.37% TMO Thermo Fisher Scientific Inc $659.71 +1.19% AMGN Amgen Inc. $415.61 +2.01% GILD Gilead Sciences, Inc. $151.28 +2.84% ABT Abbott Laboratories $99.16 +0.68% NVO Novo Nordisk A/S $38.39 +0.54%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides